Please login to the form below
Alzheimer
This page shows the latest Alzheimer news and features for those working in and with pharma, biotech and healthcare.
FDA grants Priority Review for Biogen and Eisai’s lecanemab for early Alzheimer’s disease
Lecanmab is being evaluated in the ongoing phase 3 Clarity Alzheimer's clinical trial. ... been waiting for new treatment options to address an underlying pathology of Alzheimer’s disease.
Latest news
-
Alzheimer's Research UK supports government plans for clinical research
The charity has suggested creating a Dementia Medicines Taskforce in order to address diseases like Alzheimer's. ... Alzheimer's Research UK has shared its support for new plans from the UK government to make the UK a leader in delivering innovative
-
LifeArc partners with UK Dementia Research Institute
Conditions targeted in the research include Alzheimer’s disease, motor neurone disease, frontotemporal dementia and Parkinson’s disease. ... Established in 2017 by the Medical Research Council, Alzheimer’s Society and Alzheimer’s Research UK, the
-
TauRx shares phase 3 trial data for Alzheimer's drug
The trial assessed TauRx’s lead investigative oral drug, HMTM, which has been tested in 598 people diagnosed with Alzheimer’s. ... He added: “Today with limited treatments for Alzheimer’s, the standard of care does not impact the underlying
-
EIT Health and Biogen announce winners of first ‘neurotechprize’
The winners, Five Lives and Neurocast, were among ten finalists working to create tech solutions for Alzheimer’s disease. ... The competition, launched in late 2021, was created to help accelerate the identification of tech solutions to address the
-
Biogen and Eisai announce FDA submission for early Alzheimer’s treatment
The licence application for the treatment of mild cognitive impairment due to Alzheimer’s disease was made as part of the accelerated approval pathway programme. ... Alzheimer’s disease is a progressive and devastating disease with few treatment
More from news
Approximately 163 fully matching, plus 423 partially matching documents found.
Latest Intelligence
-
Alzheimer’s disease: the search for a cure
Over the past two decades, Alzheimer’s drug discovery has largely focused on targeting the hallmark amyloid protein. ... other than the build-up of the hallmark Alzheimer’s proteins, amyloid and tau.
-
Alzheimer’s: the search for a cure
Future Alzheimer’s research. Three points of interest critical to future Alzheimer’s research became more crystalised as a result of these studies:. ... Despite their limitations, available outcome scales, such as the Alzheimer’s Disease Assessment
-
The search for treatments for Parkinson’s disease
and Alzheimer’s diseases.
-
Alzheimer’s: the search for a cure
Tau is emerging as a target for drug development in Alzheimer’s, as well as other disorders like frontotemporal dementia. ... big diseases in the field, such as Alzheimer’s, is too limited to make near-term success likely.
-
Great expectations: the urgent need for common purpose in Alzheimer’s disease
By Andrew Harrison. A few years ago, when communicating the phase 3 data of a major trial in Alzheimer’s disease (AD), our prime goal was focused on accuracy of reporting ... Most of us will have experience of family or friends with Alzheimer’s or
More from intelligence
Approximately 10 fully matching, plus 41 partially matching documents found.
Latest appointments
-
Cognite strengthens team with two new additions
She has demonstrated real drive and talent across a wide range of disease areas including oncology, MS, diabetes and Alzheimer’s, making her ideally suited to help build successful breakthrough science
-
Metrion Biosciences establishes scientific advisory board
The new board will be chaired by Dr Keith McCullagh, Metrion’s non-executive chairman, and its members will include Dr David Reynolds, chief scientific officer at Alzheimer’s Research UK.
-
J&J’s clinical research neuroscience director joins MedAvante
Prior to this, he was medical director, global medical affairs for Janssen's Alzheimer's disease immunotherapy unit from June 2011 to May 2013.
-
Asceneuron appoints chief medical officer
Alzheimer's disease.
-
UK Dementia Research Institute names director
In his new role, Prof De Strooper will work with the institute's founding partners - the Medical Research Council, Alzheimer's Society and Alzheimer's Research UK - to develop new therapeutics
More from appointments
Approximately 0 fully matching, plus 23 partially matching documents found.
Latest from PMHub
-
In recognition of the Anniversary of Stonewall, Nucleus Global brings attention and awareness to persistent health care inequities experienced by LGBTQIA+
The RISE study includes a research registry created to help ensure the LGBTQIA+ community is represented in Alzheimer’s research.
-
Rare Disease Day – looking to the future with hope
Alzheimer’s disease).
-
Article
A glimmer of hope for Alzheimer’s patients, but at what cost? ... Alzheimer’s disease.
-
The future of dementia and the important role of healthcare communication in raising awareness
Caring for people with dementia on hospital wards. London: Alzheimer's Society; 2009. ... Dementia UK: report to the Alzheimer’s society. London: Alzheimer’s Society; 2014.
-
4 ways to recruit Alzheimer’s disease patients for your clinical trial
What key things do you need to remember to reach patients living with Alzheimer’s disease? ... Alzheimer’s disease mainly affects people over the age of 65, with the disease developing and symptoms changing over time.
More from PMHub
Approximately 6 fully matching, plus 25 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- New Omicron sub-variants cause COVID-19 cases to rise in the UK
- Sanofi Global Health unveils new nonprofit Impact brand
- Novartis announces positive phase 3 trial results for advanced oesophageal cancer
- Pfizer announces commitment to achieve Net-Zero Standard by 2040
- My journey advancing the science in pulmonary hypertension
- Dermavant publishes positive phase 3 data for treatment of plaque psoriasis
- The Power of AI in Medical Education
- First evidence-based guide launched to put patients at heart of digital innovations
- FDA grants Priority Review for Biogen and Eisai’s lecanemab for early Alzheimer’s disease
- New Swiss research reveals how Omicron evades the immune system
- Evoke Kyne Named Communiqué Communications Consultancy of the Year 2021
- Michael Grela Elected President of the Society for Health Communication
- Eli Lilly to supply US government with 150,000 additional doses of bebtelovimab
- A creative awakening – how pharma is bringing innovation to the patient journey
- EMA grants Bavarian Nordic access to PRIME scheme for RSV vaccine candidate
- NHS App to revolutionise digital health and care with major digital updates by 2023
- Pfizer/BioNTech, AZ vaccines effective against Delta COVID-19 variant after two doses
- Shionogi Europe and NHS England agree on antibiotic subscription model
PMHub
Blue Latitude Health
Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...
Latest intelligence
- Five big changes in the healthcare comms landscape
- The world of healthcare has changed very greatly in the five years since The Difference Collective launched. Our agile model and talented team have enabled us to keep pace with...
- Early communications in Pharma: How effective pre-approval comms delivers launch success
- What communications are required for a successful launch...
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
